Medizinische Klinik und Poliklinik II
Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
Document Type
- Doctoral Thesis (18)
- Journal article (4)
Keywords
- Multiples Myelom (4)
- Plasmozytom (4)
- Aspergillus fumigatus (3)
- Aspergillus (2)
- Multiple Myeloma (2)
- Natürliche Killerzelle (2)
- Transplantat-Wirt-Reaktion (2)
- Adhesive Hydrogels (1)
- Aiolos (1)
- Akute myeloische Leukämie (1)
- Alloantigen (1)
- Alloantigen Expression (1)
- Allogeneic stem cell transplantation (1)
- Antibody (1)
- Antifungal (1)
- Antigen CD40 (1)
- Antigen CD95 (1)
- Antikörper (1)
- Antimykotika (1)
- Apoptosis (1)
- Arthrose (1)
- Aspergillosis (1)
- B-Zell-Lymphom (1)
- B-Zellen (1)
- BCMA (1)
- Baff (1)
- Biolumineszenzmessung (1)
- Biomarker (1)
- Biomechanics (1)
- Blutstammzelle (1)
- Bone marrow transplantation (1)
- CD11b+ myeloid cells (1)
- CYP7A1 (1)
- Cartiage Integration (1)
- Cartilage defect (1)
- Cell migration (1)
- Cholesterinstoffwechsel (1)
- Cytoplasma (1)
- DC (1)
- Darm (1)
- Dendritische Zelle (1)
- Dendritische Zellen (1)
- Diagnostik (1)
- FP635 (1)
- FcgR (1)
- Fettleber (1)
- Fettsäurestoffwechsel (1)
- Fluoreszenzmikroskopie (1)
- Fluoreszenzproteine (1)
- Gelenkknorpel (1)
- Genexpression (1)
- Graft versus Host Disease (1)
- Graft versus Host disease (1)
- Graft-versus-host disease (1)
- GvHD (1)
- HSF1 (1)
- HST1 (1)
- Hematopoietic Cell Transplantation (1)
- Hitzeschock Proteine (1)
- Hitzeschocktranskriptionsfaktor (1)
- Hyaliner Knorpel (1)
- Hämatopoetische Stammzelltransplantation (1)
- IKZF1 (1)
- IKZF3 (1)
- Ikaros (1)
- Immunantwort (1)
- Immune cell assays (1)
- Immunologie (1)
- Immunology (1)
- Immunosuppressant (1)
- Immunreaktion (1)
- Immunsuppression (1)
- Immunsuppressiva (1)
- Immuntherapie (1)
- Immunzellassays (1)
- Infectious diseases (1)
- Infektiologie (1)
- Interleukin 6 (1)
- Kniegelenkarthrose (1)
- Knorpel (1)
- Ldlr-Knockout (1)
- Lenalidomid (1)
- Leukaemia-inhibitory factor (1)
- Light Sheet Fluorescence Microscopy (1)
- MDSC (1)
- Maus (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Molekularbiologie (1)
- Monoklonaler bispezifischer Antikörper (1)
- Mucorales (1)
- Mucormycosis (1)
- Multiple myeloma (1)
- Myc (1)
- Myelom (1)
- NAFLD (1)
- NK (1)
- NK cell (1)
- NK-DC cross-talk (1)
- Neutrophil granulocytes interaction (1)
- Neutrophiler Granulozyt (1)
- Oncostatin M (1)
- Osmr-Knockout (1)
- Peyer's patch (1)
- Punktmutation (1)
- RNS-Bindungsproteine (1)
- Resistenz (1)
- Rheumatoid arthritis (1)
- Rheumatoider arthritis (1)
- Risikofaktoren (1)
- Schimmelpilze (1)
- Small intestine (1)
- T cells (1)
- T-Lymphozyt (1)
- T-Zellen (1)
- T-cell (1)
- TCTP (1)
- TNF (1)
- TNFR2 (1)
- Therapie (1)
- Tissue Engineering (1)
- Tracer (1)
- Transkription (1)
- Tumorimmunologie (1)
- Untertyp (1)
- Wilms tumor protein 1 (1)
- YB-1 (1)
- Zellkultur (1)
- Zellmigration (1)
- acute graft-versus host disease (1)
- agonist (1)
- allogeneic stem cell transplantation (1)
- alloreactive T cells (1)
- anti-hDEC205-WT1 antibody fusion protein (1)
- antileukemia vaccine (1)
- aspergillus fumigatus (1)
- bioluminescence imaging (1)
- bispecific (1)
- bispezifisch (1)
- chimeric antigen receptor (1)
- corticosteroids and cyclophosphamide (1)
- dendritic cell-targeting (1)
- fluorescence imaging (1)
- heat shock proteins (1)
- host-pathogen interaction (1)
- immune cell recruitment (1)
- immune response (1)
- in vitro Testmodell (1)
- invasive pulmonary aspergillosis (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- mRNA translation (1)
- mRNA-Translation (1)
- memory B cells (1)
- mesenteric lymph node (1)
- mouse model (1)
- mouse models (1)
- multiple myeloma (1)
- nichtinvasive Bildgebung (1)
- oncogenic signalling network (1)
- onkogenes Signalnetzwerk (1)
- regulatory T cells (1)
- rheumatoide Arthritis (1)
- risk factors (1)
- serum retention (1)
- therapeutic strategy (1)
- therapeutisches Target (1)
- transcription (1)
- transcriptome profiling (1)
Institute
- Graduate School of Life Sciences (22) (remove)
Sonstige beteiligte Institutionen
Das Y-Box-bindende Protein 1 (YB-1) ist ein Vertreter der hochkonservierten Familie eukaryotischer Kälteschockproteine und ein DNA/RNA-bindendes Protein. In Abhängigkeit von seiner Lokalisation übernimmt es Aufgaben bei der DNA-Transkription oder mRNA-Translation. YB-1 ist ein potentielles Onkogen beim Multiplen Myelom (MM), dass in primären MM-Zellen exprimiert ist. Für die funktionellen Untersuchungen von YB-1 in der vorliegenden Arbeit wurden humane Myelomzelllinien (HMZL) verwendet, die als in vitro Modell dieser malignen B Zell-Erkrankung dienen. Aufgrund der potentiellen Expression von YB-1 im Zellkern und/oder Zytoplasma von HMZL, wurde zunächst die Lokalisation des Proteins bestimmt. Es konnte gezeigt werden, dass YB 1 in den HMZL ausschließlich im Zytoplasma lokalisiert ist. Eine Translokation von YB-1 in den Nukleus kann durch die Serin-Phosphorylierung (Aminosäure 102) in der Kälteschockdomäne induziert werden. Die analysierten Myelomzelllinien zeigen jedoch kein nukleäres YB 1 und keine S102-Phosphorylierung. Diese Ergebnisse stützen die These, dass die Regulation der mRNA-Translation im Zytoplasma die vorherrschende Funktion von YB-1 beim MM ist. YB-1 könnte über diesen Mechanismus seine anti-apoptotische Wirkung vermitteln und die MM-Zellen vor genotoxischem Stress schützen. Um YB-1-regulierte mRNAs zu identifizieren wurden YB 1-Immunpräzipitationen mit zwei HMZL, einer Maus-Plasmozytomzelllinie und einem primären Maus-Plasmazelltumor durchgeführt. Zu den YB-1-gebundenen mRNAs gehören Translationsfaktoren und ribosomale Proteine, die eine starke Beteiligung von YB-1 beim RNA-Metabolismus bestätigen. In der vorliegenden Arbeit wurden spezifisch zwei mRNA-Kandidaten untersucht, die für den malignen Phänotyp von MM-Zellen wichtig sein können: das translationell kontrollierte Tumorprotein TCTP und MYC. Sowohl TCTP als auch MYC wurden bereits in Zusammenhang mit der Proliferation und Apoptose-Resistenz von malignen Zellen beschrieben. Die immunhistochemische Untersuchung der Knochenmarkbiopsien von MM-Patienten ergab eine gute Ko-Expression von YB-1 und TCTP in intramedullären MM-Zellen, während MYC erst in extramedullärem MM-Tumormaterial verstärkt mit der hohen YB 1-Expression korreliert. Die funktionellen Analysen der Arbeit haben gezeigt, dass YB 1 für die Translation der TCTP- und MYC-mRNA essentiell ist. Es kontrolliert die Verteilung dieser mRNAs zwischen translationell aktiven und inaktiven messenger Ribonukleoprotein-Partikeln. Die shRNA-vermittelte Reduktion von YB-1 führte zur Hemmung der TCTP- und MYC-Translation in der Phase der Initiation. Um den Einfluss der Kandidaten auf das Überleben der HMZL zu untersuchen, wurden proteinspezifische Knockdown-Experimente durchgeführt. Beim shRNA-vermittelten TCTP-Knockdown konnten keine Auswirkungen auf die Proliferation oder Viabilität von MM-Zellen beobachtet werden. Im Gegensatz dazu ist MYC für das Überleben und Wachstum der HMZL ausschlaggebend, denn der MYC-Knockdown induzierte Apoptose. Wie beim YB 1-Knockdown war ein Anstieg der Caspase-Aktivität und der Zusammenbruch des mitochondrialen Membranpotentials in den HMZL nachweisbar. Da es beim MYC-Knockdown gleichzeitig zur einer Reduktion der YB 1-Protein- und mRNA-Expression kam, wurde der Einfluss von MYC auf die Transkription des YB-1-Gens untersucht. Mit Hilfe von embryonalen Mausfibroblasten, die ein induzierbares MYC als Transgen besitzen, konnte gezeigt werden, dass die Aktivierung von MYC mit einer Zunahme der YB-1-mRNA einher geht. YB-1 ist somit ein direktes Zielgen des Transkriptionsfaktors MYC. Die Ergebnisse der vorliegenden Arbeit haben zum ersten Mal ein gegenseitiges regulatorisches Netzwerk aufgezeigt, in dem YB 1 transkriptionell durch MYC reguliert wird und YB-1 für die Translation der MYC-mRNA essentiell ist. Die Ko-Expression beider Proteine trägt zum Wachstum und Überleben von malignen Plasmazellen bei.
Diverse roles of B cells in the pathophysiology of rheumatoid arthritis are now well established. B cells contribute to autoimmunity by producing autoantibodies, processing autoantigen and the production of different cytokines which are involved in the inflammatory cascade. Therefore approaches to target B lymphocytes directly or indirectly are developed for clinical practice to treat autoimmune diseases including rheumatoid arthritis. Transient B cell depletion by rituximab (anti-CD20 antibody) has gained prime importance in recent years. Meanwhile anti-CD20 mediated transient B cell depletion therapy is now used with clinical efficiency in the treatment of patients with rheumatoid arthritis. Rituximab induces noteworthy changes in the homeostasis of peripheral B cell subpopulations during the repletion phase with emerging immature B cells in peripheral blood followed by normalization of the naïve B cell pool and a longterm delay in memory B cell subsets in patients with rheumatoid arthritis. Particularly IgD+CD27+ memory B cells repopulate very slowly during B cell regeneration. In a prospective clinical study, our laboratory has shown that the overall number of memory B cells correlates well to the duration of clinical response to rituximab. Little is known about the particular molecular changes in the memory B cell repertoire after rituximab therapy. To better understand peripheral memory B cell subsets, we explored in detail the somatic mutational frequency and pattern of Ig-VH3 gene rearrangements by using a single B cell sorting technique followed by nested PCR before and up to 6 years after rituximab therapy in 18 RA patients. We compared rituximab inflicted dynamics of mutational acquisition to memory B cell repopulation in 4 healthy donors and 6 non RA patients undergoing high dose chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT). Firstly we analyzed the peripheral composition of memory B cell subsets. The phenotypic analysis of peripheral pre-switch (IgD+CD27+) and post-switch (IgD-CD27+) memory B cells did not reveal any quantitative differences in RA patients prior to B cell depletion therapy compared to healthy donors. However extending those studies in directly analysing the B cell immunoglobulin receptor from individual B cells of RA patients and healthy controls brought interesting results. Pre-switched and post-switched memory B cells showed a highly significant difference in the amount of mutations/sequence. The population of IgD+CD27+ memory B cells is comprised of non-mutated, low and highly mutated (median= 9 mutations/ sequence) rearranged Ig receptors whereas the IgD-CD27+ memory B cell compartment shows quite uniformly highly mutated (median 18 mutations/ sequence) sequences indicating a significant difference between these two groups (mutational frequencies 3.83±0.19% vs. 7.1±0.53%; P=0.0001). Profound changes were noted in the re-emerging pre-switch memory B cells (IgD+/ CD27+) after transient B cell depletion with rituximab. These cells showed over a time period of 6 years after treatment with rituximab significantly delayed acquisition of mutations in Ig receptors on the single B cell level. One year after a single course of rituximab 84% of single repopulating IgD+/CD27+ B cells were unmutated and no highly mutated Ig-VH gene rearrangements were found(P=0.0001). Over time increasing numbers of mutations could be detected i-e 7.8% during 2nd year of regeneration (P=0.0001), 14% after 4 years (n=2). Nevertheless even 6 years after rituximab, VH mutations in IgD+ memory B cells were still reduced with 27% highly mutated sequences compared to 52% pre therapy(P=0.0001). Post-therapy analysis of CDR3 length of regenerated IgD+ memory B cells revealed increased CDR3 length which also correlates well with elevated number of non-mutated VH gene rearrangements observed during repletion phase. In comparison patients undergoing high dose chemotherapy followed by allogeneic stem cell transplantation repopulated IgD+ memory cells earlier with higher numbers of mutations in IgD+ memory B cells. One year after transplantation Ig receptors showed already 22% highly mutated and 42 % unmutated VH rearrangements. These findings indicated that anti-CD20 mediated B cell depletion seems not only to delay the production of pre-switch memory B cells but also significantly affects the acquisition of mutations in the IgD+ memory B cell pool. In contrary to the mutational pattern of IgD+ memory B cells after rituximab class switched memory B cells repopulate in the periphery with quantitatively normal mutations in their Ig receptors. Although the numeric replenishment of these recirculating class-switched memory B cells was also reduced after rituximab, we found no delay in quantitative acquisition of mutations also an increased proportion of IgA expressing B cells in this memory B cell subset was detected. Our data showed that post-therapy mutational targeting in RGYW/WRCY motifs were significantly increased as compared with that of pre-treatment (27% before rituximab vs. 43% after therapy, P=0.0003) indicating that affinity maturation may operate differently in class-switched memory B cells before and after B cell depletion. These results indicate a normal development process with an unimpaired mechanism of mutational acquisition in class-switched memory B cells. These data argue for different requirements to undergo somatic hypermutations in IgD+ memory B cells in comparison to class switched memory B cells. To conclude, our work has demonstrated for the first time a delayed acquisition of somatic hypermutations at single Ig receptor VH gene rearrangements of IgD+ memory B cells in comparison to class-switched memory B cells. These results demonstrate that IgD+ memory B cells are particularly susceptible to anti-CD20 treatment in patients with rheumatoid arthritis. In addition antigenic pressure and/or selection are substantially reduced by rituximab therapy which is basically not seen in the class-switched memory compartment. These data are in line with the hypothesis that IgD+ memory B cells have distinct requirements for activating their mutational machinery compared to class-switched memory B cells which recover normal mutations during regeneration phase. The results have implications in understanding the pathophysiology of memory B cell in rheumatoid arthritis and may be helpful in designing new targeted therapies.